Targeted Oncology· @TargetedOnc · X·· 13 hours agoScore70
Body
What a remarkable day at #ESMO26 in Madrid!
INTerpath-001, VOLGA, DeLLphi-305 & CheckMate 8HW delivered major advances. COMPANION-002 sparked important debate on PFS and OS.
Celebrate progress. Challenge evidence. Keep patients first.
Thank you, @TargetedOnc!
109 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com